Bionyra Pharma
Latest round
- —
Last raised
- Oct 2026
Total raised
- $324M
Investors
- 7
About Bionyra Pharma
Bionyra Pharma SAS, established in 2025 and headquartered in Paris, France, specializes in creating biologics for immune-mediated inflammatory conditions.Bionyra Pharma specializes in the development of next-generation biologics focused on severe immune-mediated inflammatory diseases. The company’s core product offerings include a range of monoclonal antibodies and bispecific antibodies designed to target novel immune pathways, with initial applications in atopic dermatitis and inflammatory bowel disease (IBD). Notable products include BYN-002, a TL1A monoclonal antibody that incorporates half-life extension (HLE) technology, and BYN-003, a bispecific antibody targeting both TL1A and IL-23. By offering innovative therapies that reduce dosing frequency and address multiple disease drivers, Bionyra aims to provide significant improvements in patient outcomes.Bionyra Pharma’s revenue structure is primarily derived from partnerships and collaborations with biopharmaceutical companies, as well as potential future product sales. The company’s financial model is centered around the development and commercialization of its proprietary biologics, including its flagship products BYN-002, BYN-003, and BYN-001. In these transactions, Bionyra may engage in licensing agreements or strategic collaborations that facilitate the distribution and commercialization of its therapies to healthcare providers and institutions. The pricing for these products is set based on market conditions and the value provided to healthcare systems, with the objective of delivering effective treatments for patients suffering from chronic inflammatory conditions.Bionyra Pharma plans to introduce new products targeting severe immune-mediated diseases, with specific upcoming releases related to its monoclonal and bispecific antibodies. The company is also looking to expand into markets across North America and Europe by 2026.
Who invested in Bionyra Pharma
7 investors across 2 rounds
See all investors in Bionyra Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Bionyra Pharma
Who invested in Bionyra Pharma?
Bionyra Pharma has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bionyra Pharma raised?
Bionyra Pharma has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
What does Bionyra Pharma do?
Bionyra Pharma SAS, established in 2025 and headquartered in Paris, France, specializes in creating biologics for immune-mediated inflammatory conditions.
Where is Bionyra Pharma headquartered?
Bionyra Pharma is headquartered in Paris, France.
Which VCs invest in companies like Bionyra Pharma?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Bionyra Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups
Raising like Bionyra Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.